AAAAAA
Results:
1-13
|
Results: 13
Authors:
O'Donnell, RT
DeNardo, SJ
Yuan, A
Shen, S
Richman, CM
Lara, PN
Griffith, IJ
Goldstein, DS
Kukis, DL
Martinez, GS
Mirick, GR
DeNardo, GL
Meyers, FJ
Citation: Rt. O'Donnell et al., Radioimmunotherapy with In-111/Y-90-2IT-BAD-m170 for metastatic prostate cancer, CLIN CANC R, 7(6), 2001, pp. 1561-1568
Authors:
Oliver, JW
Kravitz, RL
Kaplan, SH
Meyers, FJ
Citation: Jw. Oliver et al., Individualized patient education and coaching to improve pain control among cancer outpatients, J CL ONCOL, 19(8), 2001, pp. 2206-2212
Authors:
Lara, PN
Higdon, R
Lim, N
Kwan, K
Tanaka, M
Lau, DHM
Wun, T
Welborn, J
Meyers, FJ
Christensen, S
O'Donnell, R
Richman, C
Scudder, SA
Tuscano, J
Gandara, DR
Lam, KS
Citation: Pn. Lara et al., Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment, J CL ONCOL, 19(6), 2001, pp. 1728-1733
Authors:
Meyers, FJ
O'Donnell, RT
Citation: Fj. Meyers et Rt. O'Donnell, Correspondence re: G. C. de Gast et al., phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6 : 1267-1272, 2000., CLIN CANC R, 6(10), 2000, pp. 4167-4167
Authors:
Small, EJ
Meyer, M
Marshall, ME
Reyno, LM
Meyers, FJ
Natale, RB
Lenehan, PF
Chen, L
Slichenmyer, WJ
Eisenberger, M
Citation: Ej. Small et al., Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: Results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone, J CL ONCOL, 18(7), 2000, pp. 1440-1450
Authors:
O'Donnell, RT
DeNardo, SJ
DeNardo, GL
Miers, L
Lamborn, KR
Kukis, DL
Meyers, FJ
Citation: Rt. O'Donnell et al., Efficacy and toxicity of radioimmunotherapy with Y-90-DOTA-Peptide-ChL6 for PC3-tumored mice, PROSTATE, 44(3), 2000, pp. 187-192
Authors:
Edelman, MJ
Meyers, FJ
Miller, TR
Williams, SG
Gandour-Edwards, R
White, RWD
Citation: Mj. Edelman et al., Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: A well-tolerated regimen with activity independent of p53 mutation, UROLOGY, 55(4), 2000, pp. 521-525
Authors:
Lara, PN
Kung, HJ
Gumerlock, PH
Meyers, FJ
Citation: Pn. Lara et al., Molecular biology of prostate carcinogenesis, CR R ONC H, 32(3), 1999, pp. 197-208
Authors:
Lara, PN
Meyers, FJ
Citation: Pn. Lara et Fj. Meyers, Treatment options in androgen-independent prostate cancer, CANCER INV, 17(2), 1999, pp. 137-144
Authors:
Edelman, MJ
Gandara, DR
Meyers, FJ
Ishii, R
O'Mahony, M
Uhrich, M
Lauder, I
Houston, J
Gietzen, DW
Citation: Mj. Edelman et al., Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome, CANCER, 86(4), 1999, pp. 684-688
Authors:
Meyers, FJ
Lew, D
Lara, PN
Williamson, S
Marshall, E
Balcerzak, SP
Rivkin, SE
Samlowski, W
Crawford, ED
Citation: Fj. Meyers et al., Phase II trial of edatrexate in relapsed or refractory germ cell tumors: ASouthwest Oncology Group study (SWOG 9124), INV NEW DR, 16(4), 1998, pp. 347-351
Authors:
Geyer, CE
Green, SJ
Moinpour, CM
O'Sullivan, J
Goodwin, DK
Canfield, VA
Meyers, FJ
Osborne, CK
Martino, S
Citation: Ce. Geyer et al., Expanded phase II trial of paclitaxel in metastatic breast cancer: A Southwest Oncology Group study, BREAST CANC, 51(2), 1998, pp. 169-181
Authors:
Meyers, FJ
Gumerlock, PH
Chi, SG
Borchers, H
Deitch, AD
White, RWD
Citation: Fj. Meyers et al., Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors, CANCER, 83(12), 1998, pp. 2534-2539
Risultati:
1-13
|